Keyphrases
Hyperglycemia
100%
PARP Inhibitor (PARPi)
100%
Db Mouse
100%
Nephropathy
100%
Type 2 Diabetic
100%
Poly(ADP-ribose) Polymerase
83%
PJ34
83%
INO-1001
83%
Podocyte
50%
Diabetes
33%
Type 2 Diabetes Mellitus (T2DM)
33%
Reactive Oxygen Species Production
33%
Poly(ADP-ribose)
33%
Nuclear factor-B
33%
Diabetic Nephropathy
33%
Nuclear Translocation
16%
Oxidative Stress
16%
Pathophysiology
16%
Novel Therapeutic Targets
16%
Phosphorylation
16%
Modified Proteins
16%
Disease-associated
16%
Protein Level
16%
Downstream Targets
16%
High Glucose
16%
Drinking Water
16%
Urinary Albumin Excretion
16%
Diabetic Kidney
16%
Mitochondrial Depolarization
16%
Mesangial Expansion
16%
Glomerulopathy
16%
Glucose Treatment
16%
LepR
16%
Podocyte Depletion
16%
Podocyte Apoptosis
16%
Medicine and Dentistry
Hyperglycemia
100%
Diabetes Mellitus
100%
PARP Inhibitor
100%
Nephropathy
100%
Poly ADP Ribose Polymerase
83%
Podocyte
83%
In Vitro
33%
Diabetes
33%
Reactive Oxygen Species
33%
Maturity Onset Diabetes of the Young
33%
Adenosine Diphosphate
33%
Diabetic Nephropathy
33%
Nuclear Factor
33%
Alternative Complement Pathway C3 C5 Convertase
33%
Disease
16%
Oxidative Stress
16%
Programmed Cell Death
16%
Pathophysiology
16%
Glomerulopathy
16%
Kidney Hypertrophy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperglycemia
100%
Diabetes Mellitus
100%
Kidney Disease
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
83%
Reactive Oxygen Metabolite
33%
Nuclear Factor
33%
Alternative Complement Pathway C3 C5 Convertase
33%
Diabetic Nephropathy
33%
Adenosine Diphosphate
33%
Non Insulin Dependent Diabetes Mellitus
33%
Disease
16%
Pathophysiology
16%
Db/Db Mouse
16%
Glomerulopathy
16%
Kidney Hypertrophy
16%